OPIS PRZYPADKU
Treatment of Asymptomatic Idiopathic Intracranial Hypertension
Więcej
Ukryj
1
Consultant Neurologist, NMC Royal Hospital Sharjah, United Arab Emirates
2
Specialist Ophthalmologist, NMC Royal Hospital Sharjah, United Arab Emirates
3
Specialist Radiologist, NMC Royal Hospital Sharjah, United Arab Emirates
A - Koncepcja i projekt badania; B - Gromadzenie i/lub zestawianie danych; C - Analiza i interpretacja danych; D - Napisanie artykułu; E - Krytyczne zrecenzowanie artykułu; F - Zatwierdzenie ostatecznej wersji artykułu
Data nadesłania: 28-01-2025
Data ostatniej rewizji: 10-03-2025
Data akceptacji: 19-05-2025
Data publikacji: 02-07-2025
Autor do korespondencji
Venkatesh Manchikanti
Specialist Ophthalmologist, Specialist Ophthalmologist, NMC Royal Hospital, Sharjah, United Arab Emirates., United Arab Emirates
Ophthalmology 2025;28(1):37-40
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Introduction: Idiopathic intracranial hypertension is a neuro-metabolic disorder comprising elevated cerebrospinal fluid pressure of unknown cause, which occurs commonly in women with obesity. Idiopathic intracranial hypertension is frequently diagnosed due to increased awareness and knowledge of magnetic resonance imaging findings. The first approach in such a situation is to rule out pseudo papilledema, to confirm the findings on magnetic resonance imaging, and to further confirm with lumbar puncture. Limited literature is available regarding the presentation and prognosis of asymptomatic idiopathic intracranial hypertension. Papilloedema may be incidentally observed during routine fundus examination in patients with symptoms. Case report: This case report describes the clinical presentation, diagnostic evaluation, and management of a 21-year-old female with asymptomatic idiopathic intracranial hypertension. The patient was found incidentally with bilateral papilledema during a regular health check-up, prompting a thorough investigation to rule out secondary causes of elevated intracranial pressure. The patient was initially managed with topiramate for 6 months. A resolving trend of papilledema was seen during the follow-up period of 3 months. Conclusions: The report highlights the challenges in managing asymptomatic idiopathic intracranial hypertension, emphasising the importance of a multidisciplinary approach for optimal patient care.
REFERENCJE (13)
1.
Wall M, White WN: Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci. 1998; 39: 134–142.
2.
Mollan SP, Davies B, Silver NC, et al.: Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018; 89(10): 1088–1100.
3.
Thaller M, Homer V, Hyder Y, et al.: The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. J Neurol. 2022; 270: 851–863.
4.
Thaller M, Homer V, Mollan SP, et al.: Asymptomatic idiopathic intracranial hypertension: prevalence and prognosis. Clinical & Experimental Ophthalmology. 2023 Aug; 51(6): 598–606.
5.
Vosoughi AR, Margolin EA, Micieli JA, et al.: Idiopathic intracranial hypertension: incidental discovery versus symptomatic presentation. Journal of Neuro-Ophthalmology. 2022; 42(2): 187–191.
6.
Toscano S, Lo Fermo S, Reggio E, et al.: An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. Journal of Neurology. 2021; 268: 3249–3268.
7.
Bassan H, Berkner L, Stolovitch C, et al.: Asymptomatic idiopathic intracranial hypertension in children. Acta Neurologica Scandinavica. 2008; 118(4): 251–255.
8.
Smith SV, Friedman DI: The idiopathic intracranial hypertension treatment trial: a review of the outcomes. Headache: The Journal of Head and Face Pain. 2017; 57(8): 1303–1310.
9.
Friedman DI, Quiros PA, Subramanian PS, et al.: NORDIC IIHTT Study Group. Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache: The Journal of Head and Face Pain. 2017; 57(8): 1195–1205.
10.
Mollan SP, Sinclair AJ: Outcomes measures in idiopathic intracranial hypertension. Expert Rev Neurother. 2021; 21: 687–700.
11.
Yiangou A, Mitchell JL, Fisher C, et al.: Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation.
12.
Headache. 2021; 61: 157–169.
13.
Mollan SP, Virdee JS, Bilton EJ, et al.: Headache for ophthalmologists: current advances in headache understanding and management. Eye (Lond) 2021; 35: 1574–1586.